Publication: HLA-B*13 :01 Is a Predictive Marker of Dapsone-Induced Severe Cutaneous Adverse Reactions in Thai Patients
dc.contributor.author | Patompong Satapornpong | en_US |
dc.contributor.author | Jirawat Pratoomwun | en_US |
dc.contributor.author | Pawinee Rerknimitr | en_US |
dc.contributor.author | Jettanong Klaewsongkram | en_US |
dc.contributor.author | Nontaya Nakkam | en_US |
dc.contributor.author | Thanyada Rungrotmongkol | en_US |
dc.contributor.author | Parinya Konyoung | en_US |
dc.contributor.author | Niwat Saksit | en_US |
dc.contributor.author | Ajanee Mahakkanukrauh | en_US |
dc.contributor.author | Warayuwadee Amornpinyo | en_US |
dc.contributor.author | Usanee Khunarkornsiri | en_US |
dc.contributor.author | Therdpong Tempark | en_US |
dc.contributor.author | Kittipong Wantavornprasert | en_US |
dc.contributor.author | Pimonpan Jinda | en_US |
dc.contributor.author | Napatrupron Koomdee | en_US |
dc.contributor.author | Thawinee Jantararoungtong | en_US |
dc.contributor.author | Ticha Rerkpattanapipat | en_US |
dc.contributor.author | Chuang Wei Wang | en_US |
dc.contributor.author | Dean Naisbitt | en_US |
dc.contributor.author | Wichittra Tassaneeyakul | en_US |
dc.contributor.author | Manasalak Ariyachaipanich | en_US |
dc.contributor.author | Thapana Roonghiranwat | en_US |
dc.contributor.author | Munir Pirmohamed | en_US |
dc.contributor.author | Wen Hung Chung | en_US |
dc.contributor.author | Chonlaphat Sukasem | en_US |
dc.contributor.other | Ramathibodi Hospital | en_US |
dc.contributor.other | University of Phayao | en_US |
dc.contributor.other | Xiamen Chang Gung Hospital | en_US |
dc.contributor.other | Chang Gung Memorial Hospital | en_US |
dc.contributor.other | Udon Thani Center Hospital | en_US |
dc.contributor.other | Prapokklao Hospital | en_US |
dc.contributor.other | Chulalongkorn University | en_US |
dc.contributor.other | Faculty of Medicine, Khon Kaen University | en_US |
dc.contributor.other | Rangsit University | en_US |
dc.contributor.other | King Chulalongkorn Memorial Hospital | en_US |
dc.contributor.other | University of Liverpool | en_US |
dc.contributor.other | Faculty of Medicine Ramathibodi Hospital, Mahidol University | en_US |
dc.contributor.other | Huachiew Chalermprakiet University | en_US |
dc.contributor.other | Khon Kaen Regional Hospital | en_US |
dc.contributor.other | Faculty of Medicine, Chulalongkorn University | en_US |
dc.contributor.other | ANAN Hospital | en_US |
dc.contributor.other | The Thai Severe Cutaneous Adverse Drug Reaction (THAI-SCAR) Research Group | en_US |
dc.date.accessioned | 2022-08-04T08:50:19Z | |
dc.date.available | 2022-08-04T08:50:19Z | |
dc.date.issued | 2021-05-04 | en_US |
dc.description.abstract | HLA-B*13:01 allele has been identified as the genetic determinant of dapsone hypersensitivity syndrome (DHS) among leprosy and non-leprosy patients in several studies. Dapsone hydroxylamine (DDS-NHOH), an active metabolite of dapsone, has been believed to be responsible for DHS. However, studies have not highlighted the importance of other genetic polymorphisms in dapsone-induced severe cutaneous adverse reactions (SCAR). We investigated the association of HLA alleles and cytochrome P450 (CYP) alleles with dapsone-induced SCAR in Thai non-leprosy patients. A prospective cohort study, 16 Thai patients of dapsone-induced SCARs (5 SJS-TEN and 11 DRESS) and 9 Taiwanese patients of dapsone-induced SCARs (2 SJS-TEN and 7 DRESS), 40 dapsone-tolerant controls, and 470 general Thai population were enrolled. HLA class I and II alleles were genotyped using polymerase chain reaction-sequence specific oligonucleotides (PCR-SSOs). CYP2C9, CYP2C19, and CYP3A4 genotypes were determined by the TaqMan real-time PCR assay. We performed computational analyses of dapsone and DDS-NHOH interacting with HLA-B*13:01 and HLA-B*13:02 alleles by the molecular docking approach. Among all the HLA alleles, only HLA-B*13:01 allele was found to be significantly associated with dapsone-induced SCARs (OR = 39.00, 95% CI = 7.67–198.21, p = 5.3447 × 10−7), SJS-TEN (OR = 36.00, 95% CI = 3.19–405.89, p = 2.1657 × 10−3), and DRESS (OR = 40.50, 95% CI = 6.38–257.03, p = 1.0784 × 10−5) as compared to dapsone-tolerant controls. Also, HLA-B*13:01 allele was strongly associated with dapsone-induced SCARs in Asians (OR = 36.00, 95% CI = 8.67–149.52, p = 2.8068 × 10−7) and Taiwanese (OR = 31.50, 95% CI = 4.80–206.56, p = 2.5519 × 10−3). Furthermore, dapsone and DDS-NHOH fit within the extra-deep sub pocket of the antigen-binding site of the HLA-B*13:01 allele and change the antigen-recognition site. However, there was no significant association between genetic polymorphism of cytochrome P450 (CYP2C9, CYP2C19, and CYP3A4) and dapsone-induced SCARs (SJS-TEN and DRESS). The results of this study support the specific genotyping of the HLA-B*13:01 allele to avoid dapsone-induced SCARs including SJS-TEN and DRESS before initiating dapsone therapy in the Asian population. | en_US |
dc.identifier.citation | Frontiers in Immunology. Vol.12, (2021) | en_US |
dc.identifier.doi | 10.3389/fimmu.2021.661135 | en_US |
dc.identifier.issn | 16643224 | en_US |
dc.identifier.other | 2-s2.0-85106195756 | en_US |
dc.identifier.uri | https://repository.li.mahidol.ac.th/handle/20.500.14594/77290 | |
dc.rights | Mahidol University | en_US |
dc.rights.holder | SCOPUS | en_US |
dc.source.uri | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85106195756&origin=inward | en_US |
dc.subject | Immunology and Microbiology | en_US |
dc.subject | Medicine | en_US |
dc.title | HLA-B*13 :01 Is a Predictive Marker of Dapsone-Induced Severe Cutaneous Adverse Reactions in Thai Patients | en_US |
dc.type | Article | en_US |
dspace.entity.type | Publication | |
mu.datasource.scopus | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85106195756&origin=inward | en_US |